Despite Facing More Challenging Regulation Process Biotech Companies Showing Impressive Growth in 2012
25 July 2012 - 10:20PM
Marketwired
The Biotechnology Industry has been soaring in 2012 as companies --
both large and small -- have shown impressive growth. The SPDR
S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech
Index ETF (FBT) year-to-date are up 38 percent and 37 percent,
respectively, outperforming the broader market by a wide margin.
The Paragon Report examines investing opportunities in the
Biotechnology Industry and provides equity research on Aastrom
Biosciences, Inc. (NASDAQ: ASTM) and Geron Corporation (NASDAQ:
GERN).
Access to the full company reports can be found at:
www.ParagonReport.com/ASTM www.ParagonReport.com/GERN
Despite having to negotiate a more challenging regulation
process, biotech companies have continued to show investors strong
gains in 2012. The FDA Amendments Act of 2007 forced regulators to
increase standards for approvals of new drugs, introducing
mandatory risk evaluation and mitigation strategies. According to a
Pharmaceuticals & Biotechnology report from IMAP, several
pharmaceutical firms have altered their drug portfolios from
primary care driven blockbusters towards specialties such as
oncology, immunology and inflammation, where the medical need is
"so high that prices are more easily accepted by the
regulators."
Paragon Report releases regular market updates on the
Biotechnology Industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.ParagonReport.com and
get exclusive access to our numerous stock reports and industry
newsletters.
Aastrom Biosciences is dedicated to the development of stem cell
treatments for critical cardiovascular diseases. Aastrom is
currently evaluating its autologous cellular therapies in
late-stage U.S. clinical trials in the treatment of critical limb
ischemia (CLI) and dilated cardiomyopathy (DCM). These critical
diseases are associated with significant morbidity and mortality
and very limited treatment options.
Geron is a biopharmaceutical company developing first-in-class
therapies for cancer. The company has two lead product candidates
in clinical development, imetelstat and GRN1005. Imetelstat is a
telomerase inhibitor that is being evaluated in four Phase 2
clinical trials. GRN1005 is a peptide-drug conjugate that is
designed to transport a proven anti-cancer drug, paclitaxel.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at: http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024